Sage Therapeutics 
Welcome,         Profile    Billing    Logout  
 5 Products   3 Diseases  5 Products   9 Trials   1304 News 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zulresso (brexanolone) / Sage Therapeutics
NCT05254405: An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

Recruiting
4
20
US
Brexanolone Injection [Zulresso], Zulresso
Donald Jeffrey Newport, Sage Therapeutics
Post-Traumatic Stress Disorder
12/25
03/26
NCT05329779: Study on Allopregnanolone and Depression in Perimenopausal Women

Recruiting
4
80
US
brexanolone, Zulresso, allopregnanolone, placebo
Brigham and Women's Hospital
Depression
04/26
05/26
NCT06979544: A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

Recruiting
3
80
US
LPCN 1154A, Brexanolone, Placebo
Lipocine Inc.
Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
04/26
05/26
NCT05645432: An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

Completed
2
10
US
Brexanolone, Allopregnanolone, ZULRESSO®, SAGE-547
Sage Therapeutics
Tinnitus
11/23
11/23
NCT04468360: Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Recruiting
2
256
US
3-day differential fear conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis, U.S. P. equivalent: brexanolone (SAGE Therapeutics) (IV Allopregnanolone with Captisol), Matching IV Placebo
Boston University, National Institute of Mental Health (NIMH)
Post Traumatic Stress Disorder
12/26
12/26
NCT06580444: Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Not yet recruiting
2
40
NA
Brexanolone, Placebo
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, Sage Therapeutics, RTI International, Yale University
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
02/27
03/27
NCT05223829: Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

Active, not recruiting
1
25
US
Brexanolone, Zulresso
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Sage Therapeutics
PTSD, Alcohol Use Disorder
08/25
08/25
NCT05314153: Effects Zulresso on Postpartum Psychosis

Completed
1
10
US
Brexanolone, Zulresso
University of North Carolina, Chapel Hill, Sage Therapeutics
Postpartum Psychosis
06/24
06/24
NCT02433314: An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

No Longer Available
N/A
NA
SAGE-547
Sage Therapeutics
Super-Refractory Status Epilepticus
 
 
BRX-PPD, NCT05543746: Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

Completed
N/A
10
US
Brexanolone, Zulresso
University of North Carolina, Chapel Hill, Baszucki Brain Research Fund, Sage Therapeutics
Postpartum Depression
11/23
11/23
Zurzuvae (zuranolone) / Sage Therapeutics, Biogen
2019-002640-25: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder

Not yet recruiting
3
546
Europe
Sage-217, Capsule
Sage Therapeutics, Inc., Sage Therapeutics, Inc.
MAJOR DEPRESSIVE DISORDER, MAJOR DEPRESSIVE DISORDER, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2020-001424-34: A study to Evaluate SAGE-217 for the Treatment of Adults with Post-Partum Depression

Not yet recruiting
3
192
Europe
SAGE-217, Capsule, hard
Sage Therapeutics, Inc., Sage Therapeutics, Inc.
POSTPARTUM DEPRESSION, POSTPARTUM DEPRESSION, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT03864614: A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Hourglass Jan 2022 - Dec 2022 : Data from 50mg cohort of trial for MDD
Hourglass Oct 2021 - Dec 2021 : 1 year data from trial for MDD
Checkmark 12-month efficacy and safety data from 30 mg cohort in SHORELINE study
Mar 2021 - Mar 2021: 12-month efficacy and safety data from 30 mg cohort in SHORELINE study
Checkmark Data from 30 mg and 50 mg cohort of SHORELINE study
More
Completed
3
1515
US
SAGE-217
Biogen, Biogen
Major Depressive Disorder
06/23
06/23
AHA, NCT06759558: Allopregnanolone (Zuranolone) in Post-stroke Depression

Not yet recruiting
2
6
US
Zuranolone
Duke University, American Heart Association
Post Stroke Depression
06/26
06/26
NCT05655507: Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Completed
1
19
US
Zuranolone, SAGE-217, BIIB125
Biogen, Biogen
Major Depressive Disorder
10/24
10/24
NCT07047820: A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

Not yet recruiting
N/A
200
NA
Zuranolone, Zurzuvae, BIIB125
Biogen
Depression, Postpartum
08/26
08/26
SAGE-324 / Sage Therapeutics
NCT05366751: A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

Terminated
2/3
97
US
SAGE-324
Sage Therapeutics
Essential Tremor
09/24
09/24
KINETIC 2, NCT05173012: Study to Evaluate SAGE-324 in Participants With Essential Tremor

Completed
2
146
US
SAGE-324, SAGE-324 Matched Placebo
Sage Therapeutics, Biogen
Essential Tremor
05/24
05/24
dalzanemdor (SAGE-718) / Sage Therapeutics
NCT05655520: A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Terminated
3
153
Canada, US
SAGE-718
Sage Therapeutics
Huntington's Disease
01/25
01/25
NCT05318937: A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Completed
2
86
US
SAGE-718-matching placebo, SAGE-718
Sage Therapeutics
Parkinson Disease, Cognitive Dysfunction
01/24
02/24
NCT05358821: 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Completed
2
69
Canada, US
SAGE-718, Placebo
Sage Therapeutics
Huntington Disease
02/24
04/24
DIMENSION, NCT05107128: A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Completed
2
189
Europe, Canada, US, RoW
SAGE-718, Placebo
Sage Therapeutics
Huntington's Disease
09/24
10/24
718-CNA-202, NCT05619692: A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Completed
2
174
US
SAGE-718, SAGE-718-matching Placebo
Sage Therapeutics
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
06/24
07/24
SAGE-904 / Sage Therapeutics
No trials found
SAGE-689 / Sage Therapeutics
No trials found
Fragile X syndrome therapeutic / Sage Therapeutics
No trials found
SGE-516 / Sage Therapeutics
No trials found
SAGE-319 / Sage Therapeutics
No trials found
SAGE-421 / Sage Therapeutics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zulresso (brexanolone) / Sage Therapeutics
NCT05254405: An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

Recruiting
4
20
US
Brexanolone Injection [Zulresso], Zulresso
Donald Jeffrey Newport, Sage Therapeutics
Post-Traumatic Stress Disorder
12/25
03/26
NCT05329779: Study on Allopregnanolone and Depression in Perimenopausal Women

Recruiting
4
80
US
brexanolone, Zulresso, allopregnanolone, placebo
Brigham and Women's Hospital
Depression
04/26
05/26
NCT06979544: A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

Recruiting
3
80
US
LPCN 1154A, Brexanolone, Placebo
Lipocine Inc.
Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
04/26
05/26
NCT05645432: An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

Completed
2
10
US
Brexanolone, Allopregnanolone, ZULRESSO®, SAGE-547
Sage Therapeutics
Tinnitus
11/23
11/23
NCT04468360: Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Recruiting
2
256
US
3-day differential fear conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis, U.S. P. equivalent: brexanolone (SAGE Therapeutics) (IV Allopregnanolone with Captisol), Matching IV Placebo
Boston University, National Institute of Mental Health (NIMH)
Post Traumatic Stress Disorder
12/26
12/26
NCT06580444: Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Not yet recruiting
2
40
NA
Brexanolone, Placebo
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, Sage Therapeutics, RTI International, Yale University
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
02/27
03/27
NCT05223829: Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

Active, not recruiting
1
25
US
Brexanolone, Zulresso
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Sage Therapeutics
PTSD, Alcohol Use Disorder
08/25
08/25
NCT05314153: Effects Zulresso on Postpartum Psychosis

Completed
1
10
US
Brexanolone, Zulresso
University of North Carolina, Chapel Hill, Sage Therapeutics
Postpartum Psychosis
06/24
06/24
NCT02433314: An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

No Longer Available
N/A
NA
SAGE-547
Sage Therapeutics
Super-Refractory Status Epilepticus
 
 
BRX-PPD, NCT05543746: Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

Completed
N/A
10
US
Brexanolone, Zulresso
University of North Carolina, Chapel Hill, Baszucki Brain Research Fund, Sage Therapeutics
Postpartum Depression
11/23
11/23
Zurzuvae (zuranolone) / Sage Therapeutics, Biogen
2019-002640-25: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder

Not yet recruiting
3
546
Europe
Sage-217, Capsule
Sage Therapeutics, Inc., Sage Therapeutics, Inc.
MAJOR DEPRESSIVE DISORDER, MAJOR DEPRESSIVE DISORDER, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2020-001424-34: A study to Evaluate SAGE-217 for the Treatment of Adults with Post-Partum Depression

Not yet recruiting
3
192
Europe
SAGE-217, Capsule, hard
Sage Therapeutics, Inc., Sage Therapeutics, Inc.
POSTPARTUM DEPRESSION, POSTPARTUM DEPRESSION, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT03864614: A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Hourglass Jan 2022 - Dec 2022 : Data from 50mg cohort of trial for MDD
Hourglass Oct 2021 - Dec 2021 : 1 year data from trial for MDD
Checkmark 12-month efficacy and safety data from 30 mg cohort in SHORELINE study
Mar 2021 - Mar 2021: 12-month efficacy and safety data from 30 mg cohort in SHORELINE study
Checkmark Data from 30 mg and 50 mg cohort of SHORELINE study
More
Completed
3
1515
US
SAGE-217
Biogen, Biogen
Major Depressive Disorder
06/23
06/23
AHA, NCT06759558: Allopregnanolone (Zuranolone) in Post-stroke Depression

Not yet recruiting
2
6
US
Zuranolone
Duke University, American Heart Association
Post Stroke Depression
06/26
06/26
NCT05655507: Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Completed
1
19
US
Zuranolone, SAGE-217, BIIB125
Biogen, Biogen
Major Depressive Disorder
10/24
10/24
NCT07047820: A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

Not yet recruiting
N/A
200
NA
Zuranolone, Zurzuvae, BIIB125
Biogen
Depression, Postpartum
08/26
08/26
SAGE-324 / Sage Therapeutics
NCT05366751: A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

Terminated
2/3
97
US
SAGE-324
Sage Therapeutics
Essential Tremor
09/24
09/24
KINETIC 2, NCT05173012: Study to Evaluate SAGE-324 in Participants With Essential Tremor

Completed
2
146
US
SAGE-324, SAGE-324 Matched Placebo
Sage Therapeutics, Biogen
Essential Tremor
05/24
05/24
dalzanemdor (SAGE-718) / Sage Therapeutics
NCT05655520: A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Terminated
3
153
Canada, US
SAGE-718
Sage Therapeutics
Huntington's Disease
01/25
01/25
NCT05318937: A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Completed
2
86
US
SAGE-718-matching placebo, SAGE-718
Sage Therapeutics
Parkinson Disease, Cognitive Dysfunction
01/24
02/24
NCT05358821: 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Completed
2
69
Canada, US
SAGE-718, Placebo
Sage Therapeutics
Huntington Disease
02/24
04/24
DIMENSION, NCT05107128: A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Completed
2
189
Europe, Canada, US, RoW
SAGE-718, Placebo
Sage Therapeutics
Huntington's Disease
09/24
10/24
718-CNA-202, NCT05619692: A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Completed
2
174
US
SAGE-718, SAGE-718-matching Placebo
Sage Therapeutics
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
06/24
07/24
SAGE-904 / Sage Therapeutics
No trials found
SAGE-689 / Sage Therapeutics
No trials found
Fragile X syndrome therapeutic / Sage Therapeutics
No trials found
SGE-516 / Sage Therapeutics
No trials found
SAGE-319 / Sage Therapeutics
No trials found
SAGE-421 / Sage Therapeutics
No trials found

Download Options